IDEXX Laboratories, Inc. (NASDAQ:IDXX) insider Giovani Twigge sold 2,000 shares of the company’s stock in a transaction on Thursday, November 30th. The stock was sold at an average price of $156.07, for a total value of $312,140.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) opened at $159.78 on Wednesday. IDEXX Laboratories, Inc. has a 1-year low of $113.71 and a 1-year high of $173.01. The company has a debt-to-equity ratio of -12.48, a current ratio of 0.95 and a quick ratio of 0.77. The company has a market cap of $13,893.94, a price-to-earnings ratio of 53.64, a price-to-earnings-growth ratio of 2.41 and a beta of 0.42.
IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Tuesday, October 31st. The company reported $0.79 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.05. IDEXX Laboratories had a net margin of 14.55% and a negative return on equity of 336.64%. The business had revenue of $492.00 million for the quarter, compared to analyst estimates of $492.94 million. During the same period in the prior year, the company posted $0.62 EPS. The company’s revenue for the quarter was up 9.7% on a year-over-year basis. equities research analysts anticipate that IDEXX Laboratories, Inc. will post 3.24 EPS for the current year.
A number of equities analysts have recently issued reports on the company. Stifel Nicolaus reaffirmed a “buy” rating and set a $185.00 price target on shares of IDEXX Laboratories in a research report on Tuesday, October 24th. Bank of America raised IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $175.00 target price on the stock in a research report on Wednesday, August 23rd. Canaccord Genuity reissued a “buy” rating and issued a $180.00 target price on shares of IDEXX Laboratories in a research report on Tuesday, August 22nd. Finally, Zacks Investment Research downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, October 18th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $173.67.
Several hedge funds have recently bought and sold shares of the company. D.A. Davidson & CO. lifted its stake in IDEXX Laboratories by 160.4% in the 2nd quarter. D.A. Davidson & CO. now owns 625 shares of the company’s stock valued at $100,000 after buying an additional 385 shares in the last quarter. Sun Life Financial INC lifted its stake in IDEXX Laboratories by 9,085.7% in the 2nd quarter. Sun Life Financial INC now owns 643 shares of the company’s stock valued at $104,000 after buying an additional 636 shares in the last quarter. BB&T Investment Services Inc. purchased a new position in IDEXX Laboratories in the 2nd quarter valued at about $104,000. Zions Bancorporation purchased a new position in IDEXX Laboratories in the 3rd quarter valued at about $162,000. Finally, Coastline Trust Co purchased a new position in IDEXX Laboratories in the 2nd quarter valued at about $202,000. 86.80% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: This news story was reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this news story on another website, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this news story can be viewed at https://ledgergazette.com/2017/12/06/giovani-twigge-sells-2000-shares-of-idexx-laboratories-inc-idxx-stock.html.
About IDEXX Laboratories
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
Receive News & Ratings for IDEXX Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.